AstraZeneca Oncology PSP for IMFINZI® (durvalumab) in Limited-Stage Small Cell Lung Cancer (ADRIATIC)
Dear Healthcare Provider,
We are writing to inform you of an important update specific to Québec for the eligibility criteria of the AstraZeneca Oncology PSP for IMFINZI® (durvalumab), effective immediately, for patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based CRT.
As previously communicated, the PSP for IMFINZI in LS-SCLC opened to eligible adult patients on April 15, 2025, to provide access to free drug, infusion services, and educational resources through the PSP.
To ensure that the eligibility criteria for the IMFINZI PSP for ADRIATIC are aligned with the anticipated public reimbursement criteria in Québec, please see the updated Québec-specific eligibility criteria below, with the updated criteria underlined:
- Patients meet the Health Canada approved indication: IMFINZI (durvalumab), as monotherapy, for the treatment of adult patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based CRT.
- ECOG performance status 0-1.
- Patients who have received sequential or concurrent platinum-based CRT (etoposide + carboplatin/ cisplatin) within 42 days from their planned IMFINZI infusion date.
- Patients who have completed ANY radiotherapy regimen.
In the event that changes are made to the program in the future, prescribing physicians with patients already enrolled in the program will be notified in advance. Any patients in Québec deemed eligible prior to this update will continue to receive uninterrupted access to IMFINZI, along with all the program services, for as long as they require treatment (according to the approved indication) or until public listing (whichever comes first).
To enroll a new patient in the PSP, please fax a completed enrolment form (attached) to 1-877-280-6221 or email it to the AstraZeneca Oncology Patient Support Program at enrollment@AZoncologypsp.ca.
Should you have any questions about the PSP program, please do not hesitate to contact us at 1-877-280-6208 (Monday to Friday, from 8:00 AM – 8:00 PM EST). If you have any questions about IMFINZI, please contact your local AstraZeneca Canada representative.
Regards,
Your Patient Care Coordinator
AstraZeneca Oncology Patient Support Program